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Twenty-one patients with beta-thalassemia treated with 
hypertransfusion and subcutaneous Desferrioxamine (DF) chelation 
received annual evaluations of serum ferritin level and hepatic, 
endocrine, and cardiac function. To assess the effectiveness of DF 
therapy, the patients were divided into compliant (N=ll) and 
noncompliant (N=10) groups and the results of their annual evaluations 
were compared. 
The compliant group showed a statistically significant drop in mean 
serum ferritin and SGOT levels not seen in the noncompliant population. 
However, the mean serum ferritin levels of the compliant group plateaued 
at 3,000 ng/ml, indicating that the DF dose was not sufficient to 
further reduce body iron stores. There was a significantly decreased 
incidence of impaired carbohydrate metabolism in the compliant group as 
compared with the noncompliant one. Mo difference in the incidence of 
growth curve abnormalities was found, but bone age and pubertal 
development both appeared to be normalized by compliance with DF if the 
drug was begun at an early age. Echocardiograms suggested that left 
ventricular hypertrophy might be prevented or delayed by compliance with 
a 5 night/week regime, but this regime's overall effectiveness in 




It is concluded that subcutaneous DF chelation is helping to at 
delay some of the complications of iron overload but that earlier 
intensive chelation is needed. 
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1 . 1 INTRODUCTION 
In 1925, Thomas Cooley and Pearl Lee first described the clinical 
syndrome of "anemia, splenomegaly, and some enlargement of the 
liver,...[as well as]... a peculiar mongoloid appearance, caused by 
enlargement of the cranial and facial bones, combined with the skin 
discoloration." (Cooley 1925) This syndrome later came to be known 
(after the senior author) as Cooley's anemia. Since then, the medical 
profession has learned a great deal about the genetics, clinical 
manifestations, and treatment of this disease, which is now commonly 
referred to as homozygous beta thalassemia, the eponym "Cooley's anemia" 
having fallen into slight disfavor because of its unintended racial 
connotations. The term "thalassemia" is derived from the Greek words 
for "sea" and "blood", indicating that the population most afflicted by 
this disorder is from the countries bordering the Mediterranean Sea, 
particularly Greece and Italy. (Lin-Fu 1981) 
Thalassemia is an autosomal recessively inherited genetic defect in 
which there is diminished or absent synthesis of the beta-globin chain 
of normal hemoglobin A. Recombinant DNA technology has revealed that 
the molecular basis for thalassemia is quite heterogeneous. More than 




from point mutations that change "sense" codons to give incorrect 
signals to unequal crossover and recombination of closely linked genes 
to full or partial deletion of the gene. All of the mutations in some 
way prevent the beta-globin gene from producing mRNA template in 
sufficient amounts; most commonly, by causing "premature termination of 
translation or abnormal processing of mRNA precursor." (Pearson and 
Benz) 
The anemia of the homozygous state of beta-thalassemia, known as 
thalassemia major, is due not only to the decrease or lack of production 
of Hb A, but also to the increased hemolysis thought to be brought about 
by an excess of unpaired alpha chains that precipitate and form 
inclusion bodies called Fessas bodies. Beta thalassemia major is 
characterized by an untransfused hemoglobin level of 5 g/dl or less. 
Microcytes, bizarre poikilocytes, target cells, and increased numbers of 
white blood cells and nucleated red blood cells are typically seen on 
peripheral blood smear. Hemoglobin electrophoresis reveals reduced 
amounts or a complete absence of Hb A, with relatively increased Hb A2 
and Hb F. (Pearson and Benz) 
The heterozygous state, referred to as thalassemia trait, produces 
only a mild anemia (hemoglobin 1-2 g/dl below normal) that is usually 
asymptomatic and may go undiagnosed. Peripheral smear shows many of the 
same abnormalities seen in thalassemia major but to a lesser degree. 
Definitive diagnosis is usually made by demonstration of increased 
amounts of Hb A2 relative to Hb A, but for mass screening purposes, 
simpler tests such as determination of MCV or osmotic fragility are 
generally employed. (Pearson and Benz) 
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Thalassemia intermedia is a clinical classification for thalassemics 
who are able to maintain their hemoglobin levels between 7 and 9 g/dl 
without regular transfusions. The genetic disorder behind this clinical 
presentation can be either mild homozygous beta thalassemia or severe 
heterozygous beta thalassemia, more commonly the former. (Lin-Fu 1981) 
These patients tend to do better clinically, but may still suffer many 
of the complications of anemia and iron overload seen in thalassemia 
major and described below. (Pearson and Benz) The treatment of 
thalassemia intermedia is controversial. The criteria used by the Yale 
New Haven Hospital Pediatrics Department in deciding to put a patient 
with thalassemia intermedia on hypertransfusion therapy include 
nonspecific symptoms such as weakness and fatigue, progressive 
disfiguring bone changes, and evidence of cardiac dysfunction secondary 
to anemia such as cardiomegaly or tachycardia. 
1.2 CLASSICAL PRESENTATION OF THALASSEMIA MAJOR 
Before the introduction of hypertransfusion and iron chelation 
therapies, the classical presentation of thalassemia major was quite 
distinctive. Because the production of fetal hemoglobin, the 
predominant hemoglobin during intrauterine life, is normal, the child 
appears normal at birth. But within three to twelve months some of the 
first symptoms, including pallor, fever, recurrent infections, jaundice, 
epistaxis, constipation, diarrhea, splenomegaly, and general weakness, 
begin to appear. (Lin-Fu 1981) With increasing age, the child develops 
symptoms related to the body's attempt to cope with the severe anemia. 
Ineffective hematopoiesis causes expansion of the bone marrow and 
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resulting skeletal changes in the ribs, skull, long bones of the 
extremities, and short bones of the hands and feet. Overgrowth of the 
maxilla produces the typical facies of thalassemia with short nose, 
prominent eyes, high, protruding cheek bones, overbite and malocclusion. 
(Lin-Fu 1981) Osteoporosis and pathological fractures are fairly common. 
Cardiomegaly secondary to anemia and abdominal enlargement due to 
hepatosplenomegaly are inevitable. Because intestinal iron absorption 
is increased, even completely untransfused children develop iron 
overload and hemosiderosis. Growth retardation is usually severe, 
(Logethetis 1972), and secondary sex characteristics rarely develop. 
(Zaino 1969, Landau 1984) Children who are not given transfusional 
therapy at all survive an average of less than four years. Those who 
are minimally transfused to maintain a hemoglobin level between 5 and 6 
g/dl are symptomatic much of the time and generally die between the ages 
of fifteen and twenty years. (Pearson and Benz) 
1.3 HYPERTRANSFUSION THERAPY 
Until about twenty years ago, because of the fear of accelerating 
hemosiderosis and its fatal consequences, such minimal transfusions were 
the standard therapy for thalassemics. But in 1963, Irving J. Wolman 
published his seminal study "Transfusion therapy in Cooley's anemia: 
growth and health as related to long-range hemoglobin levels. A 
progress report." Wolman reported that a study of three groups of 
children maintained at different pretransfusional hemoglobin levels 
showed that the group with the highest levels had the fewest and least 
severe health problems. Those problems relating to anemia such as 
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stunted growth, bone abnormalities, and cardiomegaly were particularly 
improved. (Wolman 1964) 
With this study, Wolman introduced the concept of hypertransfusion 
therapy in which transfusions are given regularly enough to maintain a 
hemoglobin level of 9 to 10 g/dl. Since then, hyper transfusion has 
become standard practice, and the classical features of beta thalassemia 
major described above have virtually disappeared. Thalassemic children 
on hypertransfusion therapy are able to lead almost normal lives. They 
do not suffer the fatigue, irritability, and exercise intolerance 
associated with severe anemia. Cardiomegaly, hepatosplenomegaly, and 
hypersplenism are all reduced. Because erythropoiesis is suppressed, 
facial changes and osteoporosis of the long bones do not develop. Any 
such changes that are already present when hypertransfusion therapy is 
begun tend to regress. Growth, at least during the first decade of 
life, is much more normal. (Beard 1969, Piomelli 1969, Necheles 1974) 
The acceleration of hemosiderosis and consequent earlier deaths that 
were feared have not proved to be the case. This may be because Wolman 
was correct when he suggested that it was "not unlikely that the 
maintaining of normal hemoglobin levels by more frequent transfusions 
prevents undue iron absorption from the intestine." (Wolman 1964) The 
decrease in intestinal iron absorption may offset the increase in the 




An additional advancement in the care of thalassemic patients has 
been the use of splenectomy when there is evidence of hypersplenism. 
Hypersplenism usually manifests itself as an increased transfusional 
requirement because of decreased survival time of transfused red blood 
cells, but neutropenia and thrombocytoenia may also be present. A 
transfusion requirement of greater than 200 ml/kg/yr (to maintain 
hemoglobin levels greater than 9.5 g/dl) is generally felt to be an 
indication for splenectomy. Because of the increased risk of infection 
in splenectomized patients, splenectomy is deferred as long as possi. e, 
at least until after age five or six, to allow broader humeral immunity 
to develop. Polyvalent pneumococcal polysaccharide vaccine is 
administered before splenectomy, and prophylactic oral penicillin may be 
used afterwards. (Pearson and Benz) By decreasing the transfusional 
requirement in the presence of hypersplenism, splenectomy is believed to 
reduce the rate of iron loading. 
1.5 COMPLICATIONS OF IRON OVERLOAD 
Despite these advances in treatment, thalassemics suffer considerable 
morbidity and mortality beginning in their second decade due to the 
complications of iron overload. The finding of hepatic fibrosis 
associated with siderosis in thalassemics was first described in 1954 in 
post-mortem histological studies by Ellis et al. The patients in this 
study were on low transfusion regimens but presumably had additional 
iron load from increased gastrointestinal absorption on top of their 
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transfusional load. More recent studies of liver biopsy specimens have 
confirmed this finding in hypertransfused children. (Barry 1974) A 
large study by Jean et al revealed that fibrosis was limited to the 
portal spaces in children aged three to five but that by age fifteen to 
sixteen, most showed features of cirrhosis. (Jean 1984) Elevated 
transaminase levels as well as more clinically important abnormalities 
of liver function, such as hypergammaglobulinemia, hypoalbuminemia, and 
moderately decreased production of coagulation factors, are found and 
generally become worse with increasing age. (Hilgartner 1964, Pearson 
and Benz) 
The pancreas, too, undergoes siderosis and fibrosis (Ellis 1954), 
and, as might be expected, impaired carbohydrate metabolism, and even 
overt diabetes mellitus, is often seem in the second decade. (Lassman 
1974, Mecheles 1974, Flynn 1976, McIntosh 1976, Costin 1977) It is 
unclear, however, to what degree this is due to decreased insulin 
secretion from iron damaged beta cells and to what degree it is due to 
insulin resistance and hyperglucagonemia, probably related to cirrhosis. 
(Costin 1977, Zuppinger 1979) There is also some evidence that a 
familial history of diabetes increases the likelihood that a thalassemic 
patient will develop this complication. (Wolman and Ortolani 1969, 
Costin 1977, Zuppinger 1979, Modell and Berdoukas 1934) 
Growth retardation remains a confusing issue with thalassemic 
children. Although growth during the first decade of life seems to be 
improved by hypertransfusion therapy, the adolescent growth spurt and 
the onset of puberty are delayed or absent under any transfusional 
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program. (Canale 1974, Flynn 1976, Landau 1984) In general, it appears 
that it is largely anemia that retards growth during the first decade 
and hemosiderosis that retards it during the second decade. (Lin-Fu 
1981) Bone maturation is impaired. Girls frequently are oligo- or 
amenorrheic and have poor breast development. Boys often have sparse 
facial and body hair, decreased phallic development, and varying degrees 
of spermatogenesis. In general, males are somewhat more likely to 
experience difficulties with pubertal development than are females. 
(Landau 1984, Flynn 1976) Iron damage to the pituitary gland appears to 
play a larger role in the lack of pubertal development than does 
hypothalamic or end organ damage. (Kletsky 1979) 
Cardiac complications due to hemosiderosis are usually the cause of 
death in thalassemic patients. Analogous to the situation with growth, 
the cardiomegaly due to anemia during the first decade of life is 
greatly reduced or eliminated by hypertransfusion therapy, but during 
the second decade hemosiderosis produces cardiomegaly and left 
ventricular hypertrophy which progress to chronic refractory congestive 
heart failure. Pericarditis, heart block and atrial and ventricular 
arrhythmias are also common. (Engle 1964, Ehlers 1930) Most patients 
succumb to these complications between sixteen and twenty-four years of 




With the introduction of hypertransfusion therapy the interest in 
finding a good iron chelator to combat transfusional iron overload was 
increased. A number of chelating agents, including penicillamine, EDTA, 
tricalcium diethylene triamine pentaacetate, DPTA, and desferrioxamine B 
were studied. All but desferrioxamine B were found to either lack 
specifity or carry significant toxicity. (Pearson and Benz) 
Ferrioxamine B is a sideramine obtained from the bacterium 
Streptomyces pilosus. The iron is removed by chemical means to produce 
desferrioxamine B. As seen in Figure 1, desferrioxamine (DF) is made up 
of one molecule of acetic acid, two molecules of succinic acid, and 
three molecules of 1-amino-5-hydroxylamincpentane. When DF comes in 
contact with a ferric ion, it wraps around it forming three hydroxamic 
acid bonds, which makes for a very stable iron complex, as shown in 
Figure 2. (DF does not bind ferrous ions.) This chelating agent is not 
only potent, it is also very specific, showing a much higher affinity 
for iron than for any other metal. It removes iron from ferritin and 
hemosiderin but not from transferrin or from the porphyrins of 
hemoglobin, myoglobin, and the respiratory chain enzymes where the iron 
plays an essential role. (Keberle 1964, Graziano 1978) 
Unfortunately, DF is not absorbed well through the gastrointestinal 
tract, and so must be administered parenterally. Numerous studies have 
shown that continous subcutaneous or intravenous administration are much 
more effective in producing high levels of urinary iron excretion than 
are painful, intermittent intramuscular injections. (Hussain 1976, 
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Weiner 1978) Because continuous subcutaneous infusion with a portable 
pump is much more convenient and is 80-90% as effective as the 
intravenous route, (Propper 1977, Graziano 1978), subcutaneous infusion 
has become the preferred method of DF administration. With this method, 
as much as 100 mg of daily urinary excretion can be achieved in iron 
overloaded patients, (Pearson and Benz), although this amount decreases 
with decreasing iron load. (Piomelli 1985) In addition, some recent 
studies have shown that fecal iron excretion is also increased by use of 
DF and can represent approximately 25-50% of the total iron excretion. 
(Cohen 1985, Bianco 1984) 
Although DF frequently produces localized irritations and swellings 
around the site of injection, until very recently, only extremely rare 
instances of more serious side effects such as cataract formation, 
allergic reaction secondary to histamine release, and visual and 
auditory neurotoxicity had been reported. (Bloomfield 1978, Romeo 1984, 
Orton 1935) However, Olivieri's group has just published a study of 89 
transfusion-dependent patients on subcutaneous DF which found 
symptomatic auditory or visual neurotoxicity in 13 patients and 
asymptomatic toxicity in 27 more. These side effects usually occurred 
in young patients on very high doses of DF per kilogram of body weight. 
In some cases, the damage was partially or fully reversible with 
discontinuation of the DF. (Olivieri 1986) 
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1.7 THE EFFECTIVENESS OF DESFERRIOXAMINE 
Several studies have found that serum ferritin levels, which have 
been shown to correlate with total body iron stores (Saarinen 1979, 
Letsky 1974, Lipschitz 1974), are markedly reduced by use of DF. (Hyman 
1985, Wolfe 1985) In most cases these reduced levels are still in the 
thousands, far above the normal serum ferritin range of 12-300 ng/ml, 
but in one small study, Cohen et al were able to decrease serum ferritin 
levels to within normal limits through a combination of intensive 
subcutaneous and intermittent intravenous DF therapy. (Cohen 1981 and 
1985) 
Hence, the decrease in total body iron stores produced by DF therapy 
has been well established, but the question of its efficacy in delaying 
or preventing the clinical complications of iron overload remains to be 
answered. Some preliminary evidence is available. Barry et al found 
decreased amounts of hepatic fibrosis on liver biopsy in chelated as 
compared to unchelated thalassemics, (Barry 1974), and Cohen, with his 
small intensively chelated group of patients, was able to reduce liver 
iron stores to normal or near normal levels and halt the progression of 
fibrosis. (Cohen 1984) Decreased serum aminotransferase levels 
following DF chelation have also been reported. (Hoffbrand 1979, Wolfe 
1985) 
Barry et al also found that only one out of four children on 
intramuscular DF had delayed puberty as compared to four out of five 
controls who were delayed. However, in a large study done in Italy, 
Borgna-Pignatti et al found that growth and sexual maturation were not 
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improved by DF therapy. Out of 250 hypertransfused adolescents on 
intramuscular DF for 7-10 years and subcutaneous DF for 3 years, 37% 
were found to be two standard deviations below the mean for normal 
height. Sixty-seven percent of the males and 38% of the females aged 
12-13 had a complete lack of pubescent changes, and only five out of 121 
females went through menarche at a normal age and continued to have 
normal menstrual cycles thereafter. In addition, a separate analysis of 
younger children (<14 years) showed that the age at which DF treatment 
was started had no influence on sexual maturity. (Borgna-Pignatti 1985) 
The prevention of cardiac dysfunction has been given particular 
attention because of the high frequency of death from this complication. 
Kaye and Owen (1978) found fewer cardiac arrhythmias in "well-chelated" 
children on intramuscular DF, and Giardina et al (1935) showed a 
reduction in the incidence of arrhythmias in younger patients started on 
subcutaneous DF before age 13. A study of left ventricular function by 
Freeman et al (1983) suggested that in some cases cardiac function can 
be improved by intensive subcutaneous DF, and a preliminary study by 
Wolfe et al (1935) shov/s that DF may at least delay the onset of cardiac 
disease. In contrast, Borow et al (1982) found abnormal cardiac 
function in older patients despite what was believed to be "adequate" 
chelation therapy, and Hyman et al (1985) found asymptomatic cardiac 
abnormalities in three out of six young compliant patients on 
subcutaneous and intravenous DF. Overall survival rates were shown to 
be improved by DF use in a study of 92 British patients by Modell et al 
(1982), though these findings must be seen as preliminary since the 
average age of their well-chelated population was only twenty. 
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1.8 CURRENT STUDY 
As part of this ongoing effort to assess the clinical effectiveness 
of DF chelation therapy, this study reviews the annual evaluations of 
cardiac, hepatic, and endocrine function done on a group of thalassemic 
patients treated with hypertransfusion and subcutaneous DF at Yale-New 
Haven Hospital. A number of these patients have been on DF since 
pre-adolescent years and are now in the age range when complications 
might be expected. The patients are divided into groups according to 
compliance, and these groups are compared looking for statistically 
significant differences in the incidence of complications with attention 
paid to current age and the age at which DF was begun. Some 
particularly interesting individual cases are examined as well. 

Chapter II 
METHODS AND MATERIALS 
2.1 POPULATION 
The population for this study consisted of a group of twenty-five 
patients with beta-thalassemia major or thalassemia intermedia treated 
with hyper transfusion and subcutaneous DF therapy since 1977 at Yale-New 
Haven Hospital (YNHH). Four of these patients were eliminated from the 
study because they were followed on DF for less than three years and, 
therefore, evaluation of long-term effects could not be made. Two of 
the four were quite old (>21 years) when they started DF and died (one 
in an automobile accident and the other from cardiac failure) within 
three years of beginning the drug. The other two started DF at a young 
age but moved out of the area shortly thereafter and were lost to 
follow-up. 
As shown in Tables 1A and B, of the twenty-one patients used in the 
study, three (all sisters) have thalassemia intermedia treated with 
hypertransfusion therapy since age 6 or 7, and eighteen have 
beta-thalassemia major. There are 12 females and 9 males, and 12 
italians and 9 greeks. The patients range in age from 9 1/2 to 22 
years. All but four of them have undergone splenectomy. The age at 
which they began DF ranges from 4 to 14 1/2 years. Transfusional iron 




the beginning of hypertransfusion therapy, was >30 gm in all patients, 
with a range of 31 gin to 155 gm. Three of the older, noncompliant 
patients have died within the past year. There were no other deaths 
(aside from the ones in patients excluded from the study) up to this 
time. 
2.2 COMPLIANCE 
Compliance with chelation therapy was variable. Four of the older 
patients were put on a dose of 2 gm DF per night, and the other 
seventeen were put on 1.5 gm per night, giving a dose range of 23.5 to 
54.5 mg/kg/night based on weights in 1985. The patients were instructed 
to use their subcutaneous DF infusion pump for a minimum of eight hours 
per night for five consecutive nights per week. Compliance with this 
regimen was judged in two ways. First, the thalassemia nurse specialist 
who works closely with all of the patients was asked to evaluate their 
compliance based on patient and parent reports to her and on the 
frequency with which they requested nev; DF prescriptions. (Follow-up at 
the pharmacies was not possible because of the wide number of pharmacies 
used by our population.) The nurse gave each of the patients a rating 
of compliant, borderline, or noncompliant. Then, a confidential 
questionnaire was sent to each of the patients still living with a cover 
letter assuring them that their answers would be seen only by this 
investigator. They were asked to state whether they used their DF >5 
times/week, 5 times/week, 4-5 times/week, 4 times/week, 3-4 times/week, 
etc. Patients who used their DF 4-5 times/week or more were judged 
compliant; those who used it 3 or 4 times/week were called borderline 
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compliant, and those who used it less were called noncompliant. 
Patients were also asked if they used their DF any more or less in 1985 
than in previous years and whether they had periods when they did not 
use it at all in order to judge the consistency of their reports. All 
but one of the eighteen living patients responded, and all but two of 
these responses were consistent with the judgement of the nurse. The 
compliance ratings of the deceased patients were confirmed by 
conversations between their physician and their parents following their 
deaths. 
Eleven patients were clearly compliant with their DF regimen, and ten 
patients were judged to be borderline or noncompliant. One of these 
ten, patient R, was very compliant (6x/week) for the first four years of 
DF use, then became noncompliant for two years and has been borderline 
compliant for the past two years. She was given an overall rating of 
borderline, but her initial compliance is taken into account in several 
instances. For most of the data analysis and discussion in this study, 
the noncompliant and borderline patients are grouped together and called 
"noncompliant" . The mean age of the compliant population in 1985 was 
13.9, significantly lower (by 2-tailed t-test, p <.05) than the mean age 
of 17.2 of the noncompliant population. The mean ages at which the two 
groups began DF is also significantly different at 3.6 yrs for the 
compliant group and 10.8 years for the noncompliant group, (p <.05). 
These differences in age are taken into account in parts of the data 
analysis in which age could play an important role. 
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2.3 ANNUAL EVALUATIONS 
In order to assess the effectiveness of DF therapy, evaluations of 
iron load and liver, endocrine and cardiac function were done on each 
patient before beginning DF and every year thereafter. These annual 
evaluations consisted of a physical exam, including height, weight, and 
Tanner staging of sexual maturity, a serum ferritin level, liver 
function tests, an oral glucose tolerance test, an electrocardiogram or 
24-hour Holter monitor, and an echocardiogram. 
2.4 SERUM FERRITIN 
Serum ferritin levels were measured by radioimmunoassay in the YNHH 
immunology laboratory. The laboratory's range of normal for serum 
ferritin is 9-200 ng/ml. The range found in the thalassemic patients 
was approximately 800 to 8,500 ng/ml. Extremely high values (9,000 to 
11,000) associated with temporarily elevated liver function tests were 
considered to be secondary to non-A non-B hepatitis and were not 
included in the analysis. 
2.5 LIVER FUNCTION TESTS 
Measurements of SGOT, alkaline phosphatase, and direct and indirect 
bilirubin were done in the usual fashion in the chemistry laboratory of 
YNHH. The laboratory's ranges of normal are as follows: SGOT 15-30 
units, alkaline phosphatase 10-70 units, direct bilirubin <.30 mg/dl, 
and total bilirubin <1.50 mg/dl. Statistical analysis was carried out 
only on the SGOTs in part because of a large number of missing values 
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for the other tests. In addition, bilirubin levels were found to be 
within normal limits with only a few sporadic exceptions and, therefore, 
were not felt to be of much value in assessing liver function in this 
population. The alkaline phosphatase levels also posed problems because 
of their variability in growing children. 
2.6 ORAL GLUCOSE TOLERANCE TESTS 
Oral glucose tolerance tests (OGTTs) were done with a glucose load of 
1.75 gm/kg up to 100 gms. Samples of venous blood were drawn in the 
fasting state and at 15, 30, 60, 90, and 120 minutes after the glucose 
load. The tests were rated normal, impaired, or diabetic based on the 
1979 classifications of diabetes mellitus in children by the National 
Diabetes Group. (See Table 2.) Two patients who had OGTTs consistent 
with borderline impairment for one year whose tests the next year were 
well within normal limits were called normal. Family histories of 
diabetes were obtained through telephone conversations with the 
patients' parents, most of whom were felt to be reliable historians. 
2.7 GROWTH AND PUBERTAL DEVELOPMENT 
Three criteria were used to evaluate the normalcy of growth and 
development in the thalassemic children: growth curves, bone age, and 
Tanner staging numbers. The patients' heights and weights were measured 
on a regularly calibrated medical step-up scale located in the clinic 
where they receive their monthly transfusions. Growth curves for height 
were plotted on standard growth charts based on these measurements. The 
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curves were judged to be normal or abnormal by three pediatricians who 
were blinded to the compliance ratings. Curves that the clinicians 
found difficult to categorize or over which there was disagreement were 
rated borderline. Both parental heights and the use of exogenous 
reproductive hormones to promote pubertal development were taken into 
account in assigning a final rating to each curve. 
Bone ages were determined from radiographs of the left hand and wrist 
and were rated normal or delayed in comparison with chronological age 
based on the standards of Greulich and Pyle. There were no patients 
with significantly advanced bone age. 
Tanner stage was judged each year by one of two pediatric attending 
physicians or, occasionally, by members of the pediatric housestaff. 
The standard scale of 1 to 5 established by Tanner, with 1 being 
prepubertal and 5 being full adult development, was used. (Tanner 1978) 
A single number was assigned for each child for each year, representing 
the average of the ratings for breasts and pubic hair in girls and 
phallus and pubic hair in boys. Patients who required testosterone or 
estrogen supplementation to begin or complete puberty were automatically 
considered abnormal. Those who were at a Tanner stage within normal 
limits for their age without the help of exogenous hormones were 
considered to be normal. 
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2.8 CARDIAC FUNCTION 
Echocardiograms, ekgs, and, in 19S5, 24-hour Holter monitors were 
used to evaluate cardiac function. Standard 12 lead ekgs were done each 
year looking for arrhythmias, T wave changes, and evidence of LVH. 
However, the ekgs were found to be inaccurate in assessing LVH (as 
compared to echocardiographic measurements of left ventricular wall 
thickness) and inadequate for picking up minor arrhythmias. For this 
reason, 24-hour Holter monitors were done on each child during the 1985 
evaluations. Patients with only extremely rare premature atrial 
contractions (PACs) were called normal. Those with more frequent PACs, 
rare atrial couplets, junctional ectopic beats, or rare premature 
ventricular contractons (PVCs) were called borderline, and those with 
more frequent PVCs or supraventricular tachycardias such as atrial 
flutter or fibrillation or ectopic atrial tachycardia were called 
abnormal. 
Ejection fractions were calculated using the Teicholz method from 
standard M-mode echocardiograms by two pediatric cardiologists who 
double checked each other's work. The normal range for ejection 
fractions calculated by echocardiogram at YNHH is considered to be 
between 50-70%. During 1983 (and, in some cases, 1934), the left 
ventricular posterior wall thickness during end-diastole (LVPW) was also 
recorded. Normal values for LVPW based on body surface area were taken 
from the work of Roge et al. (Roge 1978) Measurements of left 
ventricular end-diastolic chamber dimension were taken into account in 
rating the LVPWs normal, borderline, or abnormal in order to assure that 
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wall thickness did not appear to be within normal limits simply because 
the wall was stretched due to ventricular dilatation. 
2.9 ANALYSIS 
Analysis of variance for repeated measures was used to determine the 
difference in trends between compliant and noncompliant groups for both 
serum ferritin levels and SGOTs. This was followed up by t-tests to 
evaluate the difference in the change in the means for each year out 
from DF. For more qualitative tests, chi-square was used to evaluate 
the differences between compliant and noncompliant groups. Because in 
most instances there was a number less than five in at least one of the 
cells for chi-square, a Fischer exact test was used to confirm the 
findings. The analyses of variance and graphs of serum ferritin and 
SGOT levels were done on Clinfo Computer Systems sponsored by the NID, 




3.1 SERUM FERRITIN 
Analysis of variance for repeated measures was done to look at the 
difference in the change in serum ferritin levels over time between the 
compliant and noncompliant groups. Two noncompliant patients and one 
compliant patient were eliminated from the analysis because their 
pre-treatment serum ferritin levels were either missing or believed to 
be falsely elevated due to hepatitis. Patient R, whose overall 
compliance rating is borderline but who was compliant with the first 
four years of DF, was grouped with the compliant patients for this 
analysis. The analysis was performed for all patients who had no 
missing values every year up to three years, four years, and five years 
out on DF. A significant difference in the trends between the two 
groups was found for all three time spans. The analysis was not done 
beyond five years because less than half of the patients have been on DF 
more than five years, and the numbers became too small. 
Two-tailed t-tests for repeated measures done for the noncompliant 
group for each year after beginning DF up to five years out showed that 
there was no significant change in serum ferritin level from pre-DF 
levels for any of the years. In the compliant group, however, there was 
a significant change in ferritin level from pre-DF levels for every year 




The direction of this change is shown in Figure 3, which gives the 
means of the serum ferritin levels of the compliant and noncompliant 
groups prior to starting DF (year 0) and every year afterward. Patient 
R's levels were averaged with the compliant group for the first four 
years and with the noncompliant group for the last four years. The 
standard errors are plotted on either side of the means to give a 
precision band. This band clearly widens after the fifth year as might 
be expected from the fall in the number of values used to determine the 
means. Years seven and eight are not shown for the compliant group 
because there were less than three measurements in those years. 
As seen in Figure 3, the mean ferritin levels for the two groups are 
almost identical at about 4,300 ng/ml prior to beginning DF. The mean 
of the compliant group falls precipitously with the start of DF to 2,785 
and remains at a level of 3,000 or less. The noncompliant group, on the 
other hand, shows no fall in serum ferritin and remains at a level 
>4,000 ng/ml for all nine years. Thus, compliance with DF produced a 
significant and sustained decrease in serum ferritin levels that was not 
seen in the noncompliant population. 
3.2 LIVER FUNCTION TESTS 
None of the twenty-one patients had SGOTs within the normal range of 
15-30 units prior to beginning DF therapy. Four of the compliant 
patients had their SGOTs fall within normal range after starting DF as 
shown in Table 3. In some others, levels fell but were still above 




Analysis of variance for repeated measures revealed that there was a 
significant difference (p <.05) in the change in SGOT over time between 
the compliant and noncompliant groups up to three years after starting 
DF. However, when the analysis was carried out to five years, the 
difference in the trends did not reach significance. 
The changes in the mean SGOT levels in each group over time are 
illustrated in Figure 4. The mean SGOTs of the two groups begin within 
ten units of each other at time 0 prior to DF but then diverge as the 
mean for the compliant group falls during the first three years on DF. 
However, in the forth and fifth years the mean SGOT of the compliant 
group rises and the widening standard errors of the two groups overlap. 
Thus, DF appears to have been effective in decreasing ongoing liver 
damage as measured by SGOT during the first few years of use but not 
over a longer period. 
3.3 ORAL GLUCOSE TOLERANCE TESTS 
As seen in Table 4, eight out of ten noncompliant patients had 
abnormal OGTTs. Five of these were rated impaired and three were fully 
diabetic. Of the eleven compliant patients, only one, pt 0 who became 
impaired just this year at age 18, had an abnormal OGTT. Of note is 
that patient R, who has an overall compliance rating of borderline but 
who was extremely compliant for the first four years of DF treatment, 
developed impairment relatively late, at age 17, two years after she 
became noncompliant with therapy. The average age of onset of 
impairment in the noncompliant population is 14.1 years with a range of 

25 
9-19 years. The average age of the compliant population is now 13.9 
years (with a range of 9 1/2 to 19 years), closely approaching the 
average age of onset of impairment in the noncompliant group. Five of 
the compliant patients are now 15 years or older, well within the age 
range for developing diabetes, and only one of them has developed any 
abnormality. This suggests that DF is at least delaying the onset of 
impaired carbohydrate metabolism in compliant patients. 
The calculated risk ratio for the entire age range of patients is 
8.9, indicating that the risk of noncompliant patients developing 
diabetes was about nine times greater than the risk among compliant 
patients. (Chi-square is significant at p <.05. ) Because abnormal 
glucose tolerance is much less commonly seen in thalassemics on any 
treatment regimen before age 11 (Zuppinger 1979, Flynn 1976, Necheles 
1974), the risk ratio was also calculated using only patients eleven 
years or older to eliminate the possibility that the younger patients 
were biasing the sample in favor of the compliant group. The risk of 
developing diabetes was 5.4 times greater in the noncompliant patients 
using this subgroup, (chi-square significant at p <.05), indicating that 
the age difference between the two groups did not bias the results. 
Previous studies have shown that there is a positive correlation 
between a family history of diabetes and the development of diabetes as 
a complication of iron overload in thalassemia (Costin 1977, Flynn 1976, 
Wolman 1969). In this study, three compliant patients and four 
noncompliant patients had a family history of adult onset diabetes 
mellitus (AODM). (Table 4) The one compliant patient who is impaired 
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did have a maternal great grandmother with AODM. Only three of the 
eight noncompliant patients with impairment had a known family history 
of diabetes, and none of the noncompliant children whose impairment is 
known to have begun at age 13 or less had a positive family history. 
This finding indicates that the early onset of impairment may have had 
more to do with noncompliance with DF than with genetic factors. 
3.4 GROWTH AND PUBERTAL DEVELOPMENT 
As seen in Table 5, there was essentially no difference between the 
compliant and noncompliant groups in the proportion of children with 
normal, borderline, or abnormal growth curves. Thus, growth did not 
correlate with DF use in a general sense, but there were some more 
subtle findings that should be noted. Despite the reported highly 
beneficial effects of hypertransfusion therapy on prepubertal growth, 
only one of the five prepubertal children had a completely normal growth 
curve. The other three compliant prepubertal children had borderline 
curves, and the one noncompliant child had an abnormal curve. The child 
with the normal curve was also the one who began DF at the earliest age 
(4 yrs). These findings suggest that early DF use may be important for 
preadolescent growth. 
A difference in propensity for growth disturbance between males and 
females was also noted. Only one of the eight males, (the 10 yr old boy 
who began DF at age 4), had a completely normal growth curve, whereas 
six of the twelve females had normal curves. Of the compliant patients, 
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80% of the males and 66.7% of the females had borderline or abnormal 
curves. In the noncompliant group, 100% of the males and only 33.3% of 
the females had borderline or abnormal curves. These figures indicate 
that noncompliant males were at greater risk of having stunted growth 
than were females but that compliant males were at no significantly 
increased risk. 
Contrary to the finding with growth curves, there was a marked 
difference in the incidence of delayed bone age between compliant and 
noncompliant groups. (Table 5) Only one compliant patient, the one who 
began DF the latest, had a delay in bone age, whereas all but two of the 
noncompliant patients had delayed bone ages. Delay in bone age also 
correlated very closely with abnormal pubertal development. The only 
two noncompliant patients who had normal bone ages were also the only 
two who had normal Tanner staging for their ages. 
Because pubertal development would not be expected before age 11, 
only patients aged 11 or more were included in the analysis of Tanner 
staging. Mine of these patients had abnormal pubertal development. 
(Table 7) All nine of them eventually received hormone replacement 
therapy. Seven of the nine abnormal patients were noncompliant with DF. 
Seven patients age 11 or more have gone through normal puberty or have 
normal Tanner ratings for their ages. (Table 6) Only two of the seven 
are noncompliant with DF. Though the more successful outcome for the 
compliant patients is obvious, chi-square did not reach significance. 
The mean age at pubarche in the normal group was 12.1 yrs with a 
range of 11.5 to 13 yrs. This differs sharply from the delayed mean age 
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at pubarche (for those who experienced it) in the abnormal group of 
approximately 14 with a range of 13-16. The two noncompliant patients 
with normal Tanner ratings for their ages did not experience pubarche 
until age 13, the late end of the normal range. 
Although the normal group is younger than the abnormal group, the 
average Tanner number at the time hormones were begun in the abnormal 
group was 2.3, and the four compliant patients aged 13 or more have now 
far surpassed that rating. On the other hand, the two noncompliant 13 
yr old boys with a Tanner rating of 2, within normal limits for their 
age, have not yet surpassed it, suggesting that their future normal 
development may be less certain. 
The mean age at which DF was begun in the normal group is 8.8 years, 
significantly lower than the mean age of 11.9 years for beginning DF 
therapy in the abnormal group. (T-test significant at p <.05. ) All the 
normally developed patients, except patient K, began DF at less than ten 
years of age, whereas all of the patients with abnormal pubertal 
development began DF at 10 years of age or more. 
The importance of the age at which DF therapy is started is 
exemplified by the case of the three sisters with thalassemia 
intermedia. All three sisters have been compliant with DF, but their 
growth and pubertal development have been very different. The eldest 
sister, who began DF at age 13, has an abnormal growth curve, delayed 
bone age, and abnormal pubertal development. Her two younger sisters, 
on the other hand, who began DF at ages 10 and 12 have had completely 
normal adolescent growth spurts and bone ages. They each underwent 
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menarche two years after beginning DF and have continued to have normal 
menstrual cycles with Tanner stages almost at the adult level. It could 
be argued that these two girls, (who are the only ones who have 
experienced spontaneous menarche without secondary amenorrhea), had an 
advantage because they have thalassemia intermedia and did not start 
hypertransfusion therapy until after age 5. However, in light of what 
happened to their sister and the fact that iron absorption from the 
gastrointestinal tract can be assumed to have been very high prior to 
the beginning of regular transfusions, much of their successful 
development can probably be attributed to their relatively early use of 
DF. 
3.5 CARDIAC STATUS 
Cardiac status was evaluated by means of LVPW thickness during 
end-diastole to look for evidence of left ventricular hypertrophy (LVH), 
24-hour Holter monitors to look for arrhythmias, and ejection fractions 
calculated from echocardiograms to look for changes in myocardial 
function. 
The LVPW thicknesses taken from 1933, before any of the patients 
developed serious heart failure, show a marked difference between the 
compliant and noncompliant populations. (Table 8) All ten of the 
compliant patients measured had normal ventricular wall thickness based 
on body surface area, whereas four out of the eight noncompliant 
patients measured had borderline or abnormally thick left ventricular 
walls. (Significant at p<.05 level by Fischer's exact test.) These 
V 
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findings provide preliminary evidence that LVH as measured by LVPW on 
echocardiogram may be prevented or delayed by DF. 
Four out of eleven compliant patients had borderline or abnormal 
Holter monitors. However, one of the four is a 12 yr old girl (pt F) 
with frequent PVCs that she has had since early childhood and that 
disappear with exercise. Her arrhythmia is not believed to be related 
to her thalassemia, and her inclusion amongst the abnormal patients is 
questionable. Five out of the nine noncompliant patients who got Holter 
monitors in 1985 had abnormalities. Details of these abnormalities are 
shown in Table 9. Though by far the most serious arrhythmias were seen 
in the three noncompliant patients who died, there is not a 
statistically significant difference in the incidence of arrhythmia 
between the compliant and noncompliant groups when minor abnormalities 
are counted. The importance of these minor arrhythmias in predicting 
future, more serious irregularities is not clear, however. 
As can be seen in the samples from 1985 shown in Table 9, most of the 
calculated ejection fractions for both compliant and noncompliant 
patients fall well within the normal range of 50-70%. A few are greater 
than 70, representing a hyperdynamic state, possibly related to mild 
anemia at the time of testing. • Through out the years of testing, most 
of the patients' ejection fractions have fluctuated randomly but have 
remained within normal limits. However, two of the patients have shown 
fairly consistent trends that are of interest. (Table 10) Patient S, 
who is noncompliant, has a borderline Holter, and has already had an 
episode of pericarditis, has shown a slow steady fall in her ejection 
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fraction from 63 in 1978 to 52, (the lower limits of normal), in 1985. 
Patient 0, on the other hand, who is one of the most compliant patients, 
began DF therapy with an ejection fraction of only 46. Her ejection 
fraction continued to fall slightly for the first three years of DF, but 
over the past five years it has risen to 66, a value well within normal 
limits. 
Calculation of the mean of the ejection fractions before DF and each 
year thereafter showed that there was no difference between the 
compliant and noncompliant groups until six to eight years out when 
there were very few data points and the falling values of the three 
patients who died pulled the mean of the noncompliant group down. In 
two out of the three patients who died, the ejection fraction was well 
within the normal range until one to two years prior to death. The 
third patient, (pt U), had an ejection fraction consistently below 
normal for the six years preceding her death. However, her fall in 
ejection fraction corresponded to the start of disopyramide for atrial 
fibrillation, so the decrease in myocardial contractility may, at least 
in part, have been a drug effect. Hence, ejection fractions calculated 
by echocardiogram do not seem to have been a very sensitive measure of 





By dividing the patients in this study into compliant and 
noncompliant groups, we were able to compare a relatively well-chelated 
population with a minimally chelated one. This comparison revealed that 
steady use of subcutaneous DF produces a significant drop in serum 
ferritin and SGOT levels not seen with sporadic or infrequent use. 
Impairment of glucose tolerance was at least delayed if not prevented in 
the compliant group as compared to the noncompliant one, and bone age 
and pubertal development were markedly improved when DF was begun at an 
early age. On the other hand, there was essentially no difference in 
the incidence of growth curve abnormalities between the "well-chelated" 
and minimally chelated populations. Although some preliminary evidence 
revealed that left ventricular hypertrophy may be prevented or delayed 
by a five night/week subcutaneous DF regime, this regime's overall 
effectiveness in delaying or preventing arrhythmias and myocardial 
dysfunction was less apparent. In examining the specifics of these 
findings, a number of recommendations for future evaluation and 





Though they made a good, if imperfect, control group, the fact that 
ten out of twenty-one patients were borderline or noncompliant with 
their DF treatment is distressing. The significantly older age of the 
noncompliant group is at least in part a reflection of the tendency of 
adolescents to rebel against medical intervention. This tendancy 
towards noncompliance with DF in the teenage years has been widely noted 
(Cohen 1935, Giardina 1985, Piomelli 1985), and some authors have argued 
that starting DF at a very early age would make use of the subcutaneous 
infusion pump a routine, accepted habit so that noncompliance might be 
less of a problem in later years. (Modell and Berdoukas) The fact that 
the mean age at which DF was begun is significantly lower in the 
compliant population than in the noncompliant one supports this 
reasoning, and is just one of numerous findings in this study supporting 
the idea that the early initiation of DF chelation therapy is crucial. 
Other suggestions that have been made for reinforcing compliance include 
asking patients to keep a daily record of DF use (Modell and Berdoukas, 
Lancet 2/28/84) and asking them to use their DF more often than is 
actually felt to be necessary. (HA Pearson, personal communication) 
Sherman et al found a positive correlation between poor psychiatric 
adjustment and poor compliance in thalassemic patients and recommended 
psychiatric intervention in such cases as a means of improving 
compliance. (Sherman 1935) Persistence in the area of compliance is a 
necessity. In the words of Modell and Berdoukas, "all patients need 
unflagging encouragement to persevere with their chelation therapy." 
(Modell and Berdoukas 1984) 
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4.3 SERUM FERRITIN 
Since the ability of DF to lower serum ferritin levels is fairly well 
established, (Wolfe 1935, Hyman 1985), the fact that there was a 
significant difference in mean ferritin levels between the compliant and 
noncompliant groups acts as a confirmation of their compliance ratings. 
The lack of any fall in serum ferritin levels in the noncompliant group, 
many of whom were actually rated borderline compliant, suggests that use 
of DF less than four nights/week is basically ineffective. It is 
encouraging that the use of DF five nights/week kept serum ferritin 
levels lower on a long-term basis. However, on this regimen, the 
ferritin levels fell to a mean of approximately 3,000 ng/ml and remained 
there rather than continuing to fall. Only one child ever reached a 
level below 1,000 ng/ml (which is still five times the normal level). 
In other words, these children are clearly still iron overloaded. Cohen 
et al have shown that with a combination of intensive subcutaneous and 
intermittent intravenous DF it is possible to lower the serum ferritin 
levels of thalassemic children to within normal range. (Cohen 1981) 
Although no other group has yet been able to completely reproduce 
Cohen's results, perhaps this is the goal we should be striving for. 
4.4 LIVER FUNCTION TESTS 
The fall in SGOT levels seen in the compliant group over the first 
three years on DF is as might be expected with a decrease in iron load 
and presumably, therefore, decreased hepatocellular damage due to iron 
toxicity. The subsequent rise in SGOT in this group after three years 
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may in part have been due to chronic underlying non-A, non-B hepatitis 
secondary to transfusion. (Moroni 1984) However, the possibility of 
ongoing liver damage secondary to iron overload must be entertained. 
Cohen et al were able to demonstrate a drop in stainable liver iron in 
liver biopsy specimens from Grade IV to Grades 0-1 in his group of 
heavily chelated thalassemics whose serum ferritin levels concurrently 
fell to within normal range. We cannot assume that with serum ferritin 
levels in the 800-4,000 range our compliant patients' livers are not 
still iron overloaded or that hepatocellular damage is not still 
occurring. 
Even though SGOT levels seem more sensitive and reliable than other 
routine liver function tests in assessing the presence of ongoing 
hepatocellular damage in our thalassemic population, they are in no way 
specific to damage from iron overload and, so, are not ideal as a 
measure of the effectiveness of DF in reducing hepatic siderosis and 
fibrosis. Yet they remain our most reasonable, if imperfect, measure of 
liver status since other methods, such as nuclear magnetic resonance 
(Brasch 1984) or liver biopsy, are either too expensive and poorly 
worked out or too invasive to be used for routine evaluation. 
4.5 ORAL GLUCOSE TOLERANCE TESTS 
The use of subcutaneous DF clearly delayed the onset of impaired 
glucose tolerance in our compliant population as compared to our 
noncompliant one. This represents a new and exciting finding in that 
none of the other studies of the effectiveness of subcutaneous DF have 
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specifically addressed the problem of impaired carbohydrate metabolism. 
Unfortunately, it cannot yet be stated that the current level of DF use 
will completely prevent impaired glucose tolerance and diabetes, 
especially in light of the fact that one of our most compliant teenagers 
has developed impairment at age 18. 
Oral glucose tolerance tests seem to be a relatively sensitive and 
uncomplicated way of detecting early impairment of carbohydrate 
metabolism and can be recommended for use in yearly evaluations of 
thalassemic patients. Simultaneous measurement of insulin levels would 
give further information as to whether abnormalities were due more to 
decreased insulin secretion from the pancreas or to increased peripheral 
resistance. 
4.6 GROWTH AND DEVELOPMENT 
Our finding that the incidence of growth curve abnormalities did not 
differ significantly between compliant and noncompliant populations is 
in agreement with the findings of the large study of Italian children 
done by Borgna-Pignatti' s group. Given the positive effect of DF seen 
in other areas, these findings are somewhat surprising. Their 
explanation may lie in our observation that the only prepubescent child 
v/ith a completely normal growth curve was the one who began DF the 
earliest, at age 4, (earlier than most, if not all, of Borgna-Pignatti1s 
population). Growth may be such a sensitive parameter that it can be 
effected by even moderate iron overload. Although prepubescent growth 
abnormalities were thought to have been corrected by hypertransfusion 
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therapy, the finding of more subtle, "borderline" abnormalities in the 
three compliant pre-adolescent children who started DF later suggests 
that iron overload may already be effecting their growth and, again, 
argues for the earlier initiation of DF. 
Our data show that DF is preventing delayed bone age in compliant 
patients. The fact that DF seems to be helping bone age but not growth 
in the compliant patients and that normal growth was seen in 
noncompliant patients with delayed bone ages is curious. (Table 5) A 
more careful examination of the growth curves of the four noncompliant 
females with delayed bone age and abnormal pubertal development but 
"normal" growth curves may provide an explanation. Two of these 
patients had no recorded heights prior to the end of the adolescent 
growth spurt so that only the "tail-end" of their growth curves could be 
seen. Three of them showed an upward rise in their growth curves (two 
from the 5th to the 25th percentiles and one from the 10th to the 50th 
percentile) after age 13 1/2, that is, after the normal adolescent 
growth spurt should have been over. These observations suggest that the 
delay in bone age may actually have worked in favor of these patients 
allowing them to eventually, though belatedly, reach a normal height 
before their epiphyses fused. The observations also call into question 
the normal ratings originally given to these curves. Further study of 
the bone age-growth curve relationship in thalassemic patients would be 
of interest. 
Pubertal development in our population seemed to be improved by 
subcutaneous DF if it was begun at an early enough age. This finding is 
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not in agreement with the results of the Borgna-Pignatti study. While 
it is entirely possible that our current data, which was suggestive but 
not statistically significant, will not hold out as our compliant group 
becomes older, examination of the data from Borgna-Pignatti's work 
reveals one possible explanation for the disagreement. The median age 
of their population was 13 yrs 10 mos (with 25th and 75th percentiles of 
12 and 15 1/2 years), and the median amount of time on subcutaneous DF 
was 3 yrs 4 mos (with 25th and 75th percentiles of 3 yrs 0 mos and 3 yrs 
9 mos). By these numbers, it appears that only a small percent of their 
population within the age range of expected puberty began subcutaneous 
DF before age 10 and an even smaller number began it before age 9. In 
contrast to this, the mean age of beginning DF in our normally developed 
population was 8.9 yrs with the majority of the patients being in the 7 
to 8 year range. In addition, the ability of Borgna-Pignatti1s group to 
judge compliance in such a large, scattered population of patients might 
be questioned. The major conclusion to be drawn from this data is that 
the final word is not yet in. As Borgna-Pignatti herself states: 
It is possible that endocrine glands are extremely sensitive 
to iron toxicity and that even small amounts of it, 
accumulated in the first years of life, produce damage that 
cannot be reversed. Perhaps both hypertransfusion and 
aggressive chelation therapy must be initiated very early in 
life, around age 3 years...or possibly even earlier, to ensure 
a favorable prognosis for growth and puberty. 
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4.7 CARDIAC FUNCTION 
Our finding that ejection fractions in thalassemics did not 
deteriorate until approximately one year before death confirms the 
findings of numerous other authors. (Giardina 1935, Nienhuis 1930, Henry 
1978, Weiner 1978) Because most thalassemics patients die of cardiac 
failure, myocardial function is one of the most important parameters to 
be measured in following their course and evaluating the effectiveness 
of DF. Ejection fractions calculated from echocardiograms are clearly 
inadequate for this task, and more sensitive techniques need to be 
employed. Several such techniques have already been developed. In a 
study of twenty-four thalassemic patients, Leon et al found that using 
radionuclide cineangiography to determine ejection fractions during 
excercise often reveals myocardial dysfunction not yet apparent when 
ejection fractions are determined at rest. (Leon 1979) These findings 
were confirmed in a study by Nienhuis et al in 1980. The measurement of 
left ventricular end-systolic pressure-dimension relation developed by 
Borow's group may be even more helpful in revealing early cardiac 
abnormalities in thalassemic patients because it evaluates intrinsic 
contractile state independent of the changes in sympathetic tone and 
preload and afterload that occur with exercise, and it requires minimal 
patient cooperation. (Borov; 1982) 
While echocardiograms are not very useful in detecting early 
myocardial dysfunction, they can be used to look for left ventricular 
hypertrophy. Several authors have noted increased left ventricular wall 






(Weiner 1978, Henry 1978) Our measurements of LVPW for 1983 showed a 
significant difference between the compliant patients, who all had 
normal wall thickness based on body surface area, and the noncompliant 
patients, four of whom showed borderline or abnormally increased wall 
thickness. This finding gives a preliminary indication, first, that DF 
may be delaying or preventing left ventricular hypertrophy and, second, 
that measurement of LVPW by echocardiogram might be one reasonable 
method of detecting asymptomatic cardiac abnormalities in thalassemics. 
Yearly measurement of LVPW and correlation with both compliance and 
other measures of cardiac status will be necessary to verify these two 
hypotheses . 
The presence of mild arrhythmias in three of our patients less than 
14 years of age (two of whom were compliant) is in accord with the 
findings of mild cardiac abnormalities in young, compliant patients in 
two other recent studies. (Giardina 1985, Hyman 1985) Although the 
significance of these minor arrhythmias is not completely clear, their 
presence is somewhat alarming. Hyman et al argue that 
the presence of cardiac abnormalities in...[young, compliant 
patients]... suggests that to prevent heart damage in 
thalassemia, it may be necessary to start the hypertransfusion 
and effective chelation at a very young age, realizing that 
the amount of iron removed will be small. (Hyman 1935) 
Giardina was able to demonstrate a decreased incidence but not a 
complete disappearance of these arrhythmias with prolonged DF use. 
(Giardina 1985) The presence of arrhythmias in older, compliant 
thalassemics, though less surprising, also suggests the need for 
earlier, more intensive chelation. 
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Prolongation of life is both the ultimate measure of cardiac function 
in thalassemia and the most important goal of DF therapy. In this 
respect, the compliant group, with no deaths and no symptomatic cardiac 
dysfunction, is faring much better than the noncompliant group, 
indicating some positive effect of chelation therapy. However, the mean 
age of death in nonchelated patients as calculated by Modell and 
Berdoukas is 13 years with a range of 11-24 years, and only two of the 
compliant patients have even reached 13 much less lived beyond age 24. 
The large study of British patients done by Modell gave preliminary 
evidence that DF is prolonging life, but the definitive answer to this 
question will not be available until patients started on subcutaneous DF 
at a relatively early age have had the chance to live well into their 
20's. 
4.8 CONCLUSION 
The results of this study indicate that many of the complications of 
iron overload seen in thalassemic patients are being delayed or 
decreased in severity by subcutaneous DF therapy. However, the results 
also indicate that earlier more intensive chelation is necessary in 
order to have any hope of actually preventing complications and allowing 
these children to live relatively normal lives. 
The argument for not starting DF chelation before age 5 or 6 has been 
that net negative iron balance could not be achieved before that age 
because the iron load would not be high enough. However, Fargion et al, 
in a study of twenty-eight thalassemics from 11 months to 4 years of 
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age, showed that with a subcutaneous DF dose of 40 mg/kg, high rates of 
iron excretion could be achieved in even the youngest patients. They 
recommended that subcutaneous chelation be started as early as the third 
transfusion. (Fargion 1982) In addition, several authors have argued 
that even if net negative iron balance cannot be achieved in the very 
early years, chelation should be started to slow the rate of iron 
accumulation. An iron load high enough to easily achieve net negative 
iron balance with current doses of DF is already much too high. (Hyman 
1985, Piomelli 1985) In a study of labelled iron storage and excretion, 
Bianco et al found evidence that newly released iron "concentrates 
initially in a reticuloendothelial pool which is readily chelatable, and 
then 14-16 days]...moves to a larger and hardly chelatable storage 
pool." They, too, advise that DF chelation begin early in life before 
large amounts of iron have become part of the permanent storage pool. 
(Bianco 1984) 
The need for not only earlier but also more intensive chelation is 
suggested by serum ferritin levels of 1500 or more (1480-2800) even in 
the four patients who began DF the earliest (ages 4-6 1/2) and by levels 
up to 4000 in some of the older compliant patients. Conceivably, this 
more intensive chelation might be achieved by increasing use of the 
subcutaneous pump to 7 nights per week. But because of the difficulties 
with compliance with the pump, two investigators have found it 
beneficial to also give high dose intravenous DF with each transfusion. 
Using subcutaneous DF at 20-60 mg/kg/night for 5-6 nights per week plus 
43 hour intravenous DF (at 0.5 gm/hr) with each transfusion, Hyman has 
achieved a median serum ferritin level of 945 (with a range of 555-2300) 
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in her youngest group of patients (ages 4-9 1/2). (Hyman 1985) Cohen's 
data is less clearly presented, but he appears to have ten patients with 
serum ferritin levels less than 1000 on 2 gm/night of subcutaneous DF 
6-7 nights per week plus 24 hour intravenous infusion of 9-16 grams of 
DF every three weeks in six of the ten patients. (Cohen 1935) Cohen's 
patients begin the intravenous DF in the hospital setting with their 
transfusions and then finish it at home. Hyman has her patients 
hospitalized in socially compatible groups to receive their transfusions 
and intravenous DF, thus allowing her to incorporate an intensive 
psychosocial support program into the treatment. 
The recent finding of visual and auditory neurotoxicity in young 
thalassemics on high doses of subcutaneous DF (Olivieri 1986) suggests 
that there are limits to the dose of subcutaneous DF that can safely be 
used. However, it does not suggest that the dose of DF used in our 
population cannot be increased or that earlier chelation is unsafe if 
dosage is controlled for the weight of the child. The higher incidence 
of neurotoxicity in younger children found in the study appeared to be 
due mainly to the fact that these children were smaller and therefore 
their dose of DF per kilogram of body weight was higher. The DF dose in 
the Olivieri study ranged as high as 150 mg/kg/night whereas the dose in 
our population ranged from 23.5 to 54.5 mg/kg/night. Only three 
children in our study were on a dose as high as the 50 mg/kg/night 
recommended by the Olivieri group as being safe for younger patients. 
The most cautious approach would be a yearly analysis of DF-induced 
urinary iron excretion to find the minimum DF dose at which maximum iron 
excretion can be achieved in each patient, keeping in mind the 50 
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mg/kg/night recommendation. Complete eye examinations, audiologic 
testing, and studies of visual evoked potentials should also be done at 
least every six months, if not every three months as recommended by 
Olivieri. 
Desferrioxamine chelation is a burdensome, difficult, and expensive 
therapy. It demands an enormous expenditure of time and energy on the 
part of both the patients and their physicians, nurses, and social 
workers, who must coordinate complicated treatment plans and continually 
reinforce and encourage compliance. Successful implementation of DF 
chelation is even more difficult in many of the poorer, less medically 
well-developed Mediterranean countries in which thalassemia is most 
prevalent. However, despite these drawbacks, hypertransfusion and 
intensive DF chelation are the most promising treatment for thalassemia 
currently available. Mo successful oral chelating agent has yet been 
found, and hopes for a cure through bone marrow transplantation or 
genetic manipulation of the fetal hemoglobin gene are distant. (Lancet 
8/24/85, Lancet 1/8/83) If used intensively, desferrioxamine chelation 
offers thalassemic children the best possibility of normal growth and 
development and an extended life span, and its use should be vigorously 
continued until other solutions for the treatment of this complicated 










5t (yr : : mo) Sex ground Diagnosis (yr :mo) 
A 9 : : 6 F Italian thal maj 8: 0 
B 9 : : 6 M greek thal maj 6: 8 
C 10 : : 0 F Italian thal maj 5:10 
D 10 : ; 6 M greek thal maj 9: 8 
E 10 : ; 6 M italian thal maj 7 : 8 
F 12 : : 6 F italian thal maj 7: 7 
G 13 : : 0 M italian thal maj 5: 8 
H 13 : : 6 M greek thal maj 10: 7 
I 13 : : 6 F greek thal int not done 
J 15 : : 0 M italian thal maj not done 
K 17 : : 0 F greek thal int not done 
L 17 : : 0 M greek thal maj not done 
M 17 : : 0 M italian thal maj 5: 9 
N 17 : : 0* F italian thal maj 5: 0 
0 18: : 0 F italian thal maj 5: 0 
P 19 : 0 F greek thal int 8: 1 
Q 19 : 0 F italian thal maj 12: 4 
R 19 : 0 F italian thal maj 3: 0 
S 20 : 6 F greek thal maj 12: 8 
T 21 : 6* M greek thal maj 12: 1 
U 22: 0* 
^deceased 
F italian thal maj 10: 5 
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Table IB PATIENT POPULATION (part 2) 












A 0 : : 7 17 5 35 6: 0 1.5 borderln 
B 0 : ; 4 182 36 6: 7 1.5 comp 
C 3 : : 0 155 31 5:10 1 . 5 comp 
D 3 : ; 0 198 40 4: 0 1.5 comp 
E 0 : : 9 229 46 7: 8 1. 5 comp 
F 2 ; : 0 272 55 7 : 7 1. 5 comp 
G 0 : : 9 343 69 8:10 1 . 5 borderln 
H 0 : : 7 341 68 8: 8 1.5 borderln 
I 6 : : 0 263 53 9:11 1 . 5 comp 
J 1 : : 0 450 90 7 : 5 1 . 5 comp 
K 7 : : 0 400 80 12: 2 1.5 comp 
L 0 : : 6 510 102 9: 6 1. 5 comp 
M 0 ; : 6 495 99 10: 1 1.5 noncomp 
N 2 : : 8 461 92 11 : 2 1. 5 noncomp 
0 2 : 0 585 117 10: 3 2.0 comp 
P 9 : 0 360 72 13: 2 1.5 comp 
Q 0 : 5 459 92 11 : 8 1.5 borderln 
R 5 : 0 545 109 11 : 2 2.0 borderln 
S 0 : 6 666 133 12:11 1.5 borderln 
T 5 : 0 775 155 13: 4 2.0 borderln 
U 2 : 10 610 122 14: 5 2.0 borderln 
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Figure 1 Desferrioxamine B 
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Table 2 CLASSIFICATIONS OF DIABETES IN CHILDREN BASED ON OGTTS 
(National Diabetes Group, 1979) 
Normal = fasting venous plasma glucose <130 mg/dl 
2 hour OGTT venous plasma glucose <140 mg/dl 
Impaired = fasting venous plasma glucose <140 mg/dl 
2 hour OGTT venous plasma glucose >140 mg/dl 
Diabetic = fasting venous plasma glucose >140 mg/dl 










FOUR COMPLIANT PATIENTS WITH SGOTS THAT FELL INTO THE NORMAL RANGE 
FOLLOWING DESFERRIOXAMINE THERAPY 
Year Pt E Pt F Pt 0 Pt R 
0 101 105 59 86 
1 53 41 26 40 
2 29 33 26 24 
3 26 29 22 69 
4 29 29 40 









hr an SCOT* in Compliant va Noncoapliant Groups 









hx of AODM 
B 9 : 6 6: 7 comp nl none 
C 10 : 0 5:10 comp nl pat great uncles 
pat 2nd cousin 
D 10 : 6 4: 0 comp nl none 
E 10 : 6 7 : 8 comp nl none 
F 12 : 6 7 : 7 comp nl none 
I 13 : 6 9:11 comp nl none 
J 15 : 0 7 : 5 comp nl mat great aunt 
K 17 : 0 12: 2 comp nl none 
L 17 : 0 9: 6 comp nl none 
P 19 : 0 13: 2 comp nl none 
0 18: 0 10 : 3 comp impaired 18 : 0 mat great gm 
M 17 : 0 10: 1 noncmp nl none 
Q 19 : 0 11 : 8 brdrln nl father 
mat uncle & gm 
A 9 : 6 6: 0 brdrln impaired 9 : 0 none 
G 13 : 0 8:10 brdrln impaired 13 : 0 none 
H 13 : 6 8: 8 brdrln impaired 13 : 0 none 
N 17 : 0 11 : 2 noncmp diabetic 11 : 0 info not avail 
R 19 : 0 11 : 2 brdrln impaired 17 : 0 pat gm 
S 20 : 6 12:11 brdrln diabetic 16 : 0 none 
T 21 : 6 13: 4 brdrln impaired 19 : 0 pat gf 
U 22 : 0 14: 5 brdrln diabetic <16 : 0 pat uncle 
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Table 5 GROWTH AMD DEVELOPMENT 
Pt Ag> e 
Age DF 








D 10 : 6 4: 0 comp M normal normal not applic 
I 13 : 6 9:11 comp F normal normal normal 
K 17 : 0 12: 2 comp F normal normal normal 
B 9 : 6 6: 7 comp M brderln normal not applic 
C 10 : 0 5:10 comp F brderln normal not applic 
E 10 : 6 7: 8 comp M brderln normal not applic 
J 15 : 0 7: 5 comp M brderln normal normal 
F 12 : 6 7 : 7 comp F abnormal normal normal 
L 17 : 0 9: 6 comp M abnormal normal normal 
0 18: 0 10: 3 comp F abnormal normal abnormal 
P 19 : 0 13: 3 comp F abnormal delayed abnormal 
N 17 : 0 11 : 2 noncmp F normal delayed abnormal 
R 19 : 0 11 : 2 brderln F normal delayed abnormal 
S 20 : 6 12:11 brderln F normal delayed abnormal 
U 22 : 0 14: 5 brderln F normal delayed abnormal 
A 9 : 6 6: 0 brderln F brderln delayed not applic 
G 13 : 0 8:10 brderln M brderln normal normal 
H 13 : 6 3: 8 brderln M abnormal normal normal 
M 17 : 0 10: 1 noncmp M abnormal delayed abnormal 
Q 19 : 0 11 : 8 brderln F abnormal delayed abnormal 
T 21 : 6 13: 4 brderln M abnormal delayed abnormal 
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G 13 : 0 8:10 M 13 : 0 2 borderln 
H 13 : 6 8: 8 M 13: 0 2 borderln 
F 12 : 6 7 : 7 F 11 : 6 2 comp 
I 13: 6 9:11 F 11 : 6 *4 comp 
J 15 : 0 7 : 5 M 11 : 0 3.5 comp 
L 17 : 0 7 : 5 M <14 : 0 4 comp 
K 17 : 0 12 : 2 F 12 : 0 **4.5 comp 
^Underwent spontaneous menarche at age 12 and continues to have normal 
menstrual cycles. 


















0 18 : 0 10 : 3 F 14? 15 2 comp 
p 19 : 0 13 : 3 F 16 16 1.5 comp 
M 17 : 0 10 : 1 M none 14 1 noncmp 
N 17 : 0 11 : 2 F 13-14? 15.5 3 noncmp 
Q 19 : 0 11 : 8 F 14 16 2.5 borderIn 
R 19 : 0 11 : 2 F 14? 15 2.5 border In 
S 20 : 6 12 : 11 F 13-14? 18 **3 borderln 
T 21 : 6 13 : 4 M <16? 16.5 2 borderln 
U 22 : 0 14 : 5 F 13 19 ***3.5 borderln 
*Tanner ratings all rose to 4-5 following hormone therapy. 
**Underwent spontaneous menarche at age 14 but developed secondary 
amenorrhea after 6 months. 
***Underwent spontaneous menarche at age 13 but developed secondary 
amenorrhea after 1 year. 
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Table 8 CARDIAC STATUS 
EF by 1983 Clinical 
Pt age Compliance Holter Echo(185) LVPW Complications 
B 9 : : 6 comp nl nl (66) nl none 
C 10 : : 0 comp nl nl (58) nl none 
D 10 : : 6 comp nl nl (64) n.d. none 
E 10 : : 6 comp brdrln nl (59) nl none 
F 12 : : 6 comp ^abnormal nl (60) nl none 
I 13 : : 6 comp nl nl (58) nl none 
J 15 : : 0 comp nl nl (68) nl none 
K 17 : : 0 comp nl nl (73) nl none 
L 17 : : 0 comp nl nl (72) nl none 
0 18: : 0 comp brdrln nl (66) nl none 
P 19 : : 0 comp abnormal nl (54) nl none 
A 9 : : 6 brdrln nl nl (73) nl none 
G 13 : : 0 brdrln brdrln nl (70) nl none 
H 13 : : 6 brdrln n.d. nl (63) brdrln none 
M 17 : : 0 noncmp nl nl (66) n.d. none 
N 17 : 0 noncmp abnormal abnl (44) abnormal Pericard.(12) 
CHF,Death (17) 
0 19 : 0 brdrln nl nl (66) brdrln none 
R 19 : 0 brdrln nl nl (57) n.d. none 
S 20 : 6 brdrln brdrln brdrln(52) abnormal Pericard.(19) 
T 21 : 6 brdrln abnormal abnl (26) nl Afib (20) 
CHF,Death (21) 





Table 9 HOLTER MONITOR ABNORMALITIES 
Pt Age Compliance Holter rat: 
E 10 : 6 comp brdrln 
F 12 : 6 comp abnormal 
0 18: 0 comp brdrln 
P 19 : 0 comp abnormal 
G 13 : 0 brdrln brdrln 
N 17 : 0 noncmp abnormal 
S 20 : 6 brdrln brdrln 
T 21 : 6 brdrln abnormal 
U 22 : 0 brdrln abnormal 
Specific Abnormalities 
ext. rare JEBs, 1 PVC 
**frequent PVCs 
20 PACs in 24 hrs 
& 1 atrial couplet 
ext. rare PACs 
with 1 episode EAT 
10-30 PACs/hr, 2 conducted 
PACs & 4 atrial couplets 
Ectopic atrial tach(EAT) 
beginning at age 16 
freq. PVCs at age 17 
15 PACs & 1 atrial couplet 
15-30 PVCs/16 hrs 
Afib beginning at age 20 
freq PVCs close to death 
Begun on disopyramide for 
afib at age 16 
**PVCs have been present since early childhood and disappear with 




TWO PATIENTS WITH SIGNIFICANT TRENDS IN THEIR EJECTION FRACTIONS 









52 66 8 
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